SLC5A2 and hydrops fetalis: The composite of cardiovascular mortality or hospitalizations for HF was also reduced in patients randomized to SGLT2 inhibitors (HR 0·75; 95% CI 0·70–0·80; p<0·0001; I2=0%; Fig. 4).